medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2020, Number 3

<< Back

Alerg Asma Inmunol Pediatr 2020; 29 (3)

Biomarkers for the endotipic diagnosis of asthma and its treatment

Pizaña-Montero JA, Huerta-López JG, Pedroza MA

Language: Spanish
References: 82
Page: 99-107
PDF size: 253.57 Kb.


ABSTRACT

Asthma is one of the most worldwide prevalent chronic respiratory diseases; that usually can become severe, chronic and even refractory to standard treatments for asthma control (e.g. corticosteroids and immunomodulators). However, the recognition of two asthma endotypes based on the cytological characteristics of the immunological response (with high Th2 cellularity and eosinophils, or low cellularity of Th2) and of the cytokines produced have made it possible to identify specific therapeutic targets to stop the inflammatory cascade characteristic of asthma. To achieve this task, monoclonal antibodies have been used, which have been specifically designed for cytokines or receptors involved in asthma inflammation. This forms the basis of the biological therapy of asthma and the most current tool for the treatment and control of severe asthma and refractory to conventional treatments.


REFERENCES

  1. Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015; 5 Suppl 1: S2-S6.

  2. GINA. Global strategy for asthma management and prevention (2019 update). Disponible en: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf2019.

  3. Loureiro CC, Amaral L, Ferreira JA, Lima R, Pardal C, Fernandes I et al. Omalizumab for severe asthma: beyond allergic asthma. Biomed Res Int. 2018; 2018: 3254094-

  4. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev. 2011; 242 (1): 10-30.

  5. Harb H, Renz H. Update on epigenetics in allergic disease. J Allergy Clin Immunol. 2015; 135 (1): 15-24.

  6. Skadhauge LR, Christensen K, Kyvik KO, Sigsgaard T. Genetic and environmental influence on asthma: a population-based study of 11,688 Danish twin pairs. Eur Respir J. 1999; 13 (1): 8-14.

  7. Bunyavanich S, Schadt EE. Systems biology of asthma and allergic diseases: a multiscale approach. J Allergy Clin Immunol. 2015; 135 (1): 31-42.

  8. Yick CY, Zwinderman AH, Kunst PW, Grunberg K, Mauad T, Dijkhuis A et al. Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthma versus controls. Eur Respir J. 2013; 42 (3): 662-670.

  9. Himes BE, Jiang X, Wagner P, Hu R, Wang Q, Klanderman B et al. RNA-Seq transcriptome profiling identifies CRISPLD2 as a glucocorticoid responsive gene that modulates cytokine function in airway smooth muscle cells. PloS ONE. 2014; 9 (6): e99625.

  10. Raissy H, Blake K. Vitamin D and asthma: association, causality, or intervention? Pediatr Allergy Immunol Pulmonol. 2015; 28 (1): 60-62.

  11. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012; 18 (5): 716-725.

  12. Oliphant CJ, Barlow JL, McKenzie AN. Insights into the initiation of type 2 immune responses. Immunology. 2011; 134 (4): 378-385.

  13. Noben-Trauth N, Hu-Li J, Paul WE. IL-4 secreted from individual naive CD4+ T cells acts in an autocrine manner to induce Th2 differentiation. Eur J Immunol. 2002; 32 (5): 1428-1433.

  14. van Panhuys N, Tang SC, Prout M, Camberis M, Scarlett D, Roberts J et al. In vivo studies fail to reveal a role for IL-4 or STAT6 signaling in Th2 lymphocyte differentiation. Proc Natl Acad Sci U S A. 2008; 105 (34): 12423-12428.

  15. Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014; 108 (12): 1723-1732.

  16. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015; 16 (1): 45-56.

  17. Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2015; 15 (1): 57-65.

  18. Stokes JR, Casale TB. Characterization of asthma endotypes: implications for therapy. Ann Allergy Asthma Immunol. 2016; 117 (2): 121-125.

  19. Klein Wolterink RG, Kleinjan A, van Nimwegen M, Bergen I, de Bruijn M, Levani Y et al. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol. 2012; 42 (5): 1106-1116.

  20. Huang J, Pansare M. New treatments for asthma. Pediatr Clin North Am. 2019; 66 (5): 925-939.

  21. Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016; 137 (5): 1347-1358.

  22. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6 (11): 1123-1132.

  23. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008; 181 (6): 4089-4097.

  24. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev. 2011; 242 (1): 220-232.

  25. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest. 2010; 138 (5): 1140-1147.

  26. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013; 188 (11): 1294-1302.

  27. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S et al. Revisiting type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017; 47 (2): 161-175.

  28. Kim MA, Shin YS, Pham le D, Park HS. Adult asthma biomarkers. Curr Opin Allergy Clin Immunol. 2014; 14 (1): 49-54.

  29. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011; 184 (5): 602-615.

  30. Voraphani N, Gladwin MT, Contreras AU, Kaminski N, Tedrow JR, Milosevic J et al. An airway epithelial iNOS-DUOX2-thyroid peroxidase metabolome drives Th1/Th2 nitrative stress in human severe asthma. Mucosal Immunol. 2014; 7 (5): 1175-1185.

  31. Scott M, Raza A, Karmaus W, Mitchell F, Grundy J, Kurukulaaratchy RJ et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax. 2010; 65 (3): 258-262.

  32. I. G. Xolair Prescribing Information. Disponible en: http://www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf2010.

  33. Wadsworth S, Sin D, Dorscheid D. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. J Asthma Allergy. 2011; 4: 77-86.

  34. Excellence NIfHaC. Mepolizumab for treating severe refractory eosinophilic asthma. Disponible en: https://www.nice.org.uk/guidance/GID-TAG519/documents/html-content-32016.

  35. Turner M, Hussack P, Sears M, Dolovich J, Hargreave F. Exacerbations of asthma without sputum eosinophilia. Thorax. 1995; 50 (10): 1057-1061.

  36. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012; 130 (3): 647-654.e10.

  37. Sehra S, Yao W, Nguyen ET, Ahyi AN, Tuana FM, Ahlfeld SK et al. Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. J Immunol. 2011; 186 (8): 4959-4966.

  38. Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015; 70 (8): 748-756.

  39. Korevaar DA, Westerhof GA, Wang J, Cohen JF, Spijker R, Sterk PJ et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015; 3 (4): 290-300.

  40. Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J et al. YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J. 2010; 35 (4): 757-760.

  41. Konradsen JR, James A, Nordlund B, Reinius LE, Soderhall C, Melen E et al. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol. 2013; 132 (2): 328-35e5.

  42. Santos CB, Davidson J, Covar RA, Spahn JD. The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children. Annals of Allergy, Asthma Immunology. 2014; 113 (3): 263-266.

  43. Wedes SH, Wu W, Comhair SA, McDowell KM, DiDonato JA, Erzurum SC et al. Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children. J Pediatr. 2011; 159 (2): 248-55e1.

  44. Cowan DC, Taylor DR, Peterson LE, Cowan JO, Palmay R, Williamson A et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol. 2015; 135 (4): 877-83e1.

  45. Fan-Chung K, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ. "International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma." Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, Andrew Bush, Mario Castro, Peter J. Sterk, Ian M. Adcock, Eric D. Bateman, Elisabeth H. Bel, Eugene R. Bleecker, Louis-Philippe Boulet, Christopher Brightling, Pascal Chanez, Sven-Erik Dahlen, Ratko Djukanovic, Urs Frey, Mina Gaga, Peter Gibson, Qutayba Hamid, Nizar N. Jajour, Thais Mauad, Ronald L. Sorkness and W. Gerald Teague. Eur Respir J. 2018; 52 (1).

  46. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43 (2): 343-373.

  47. Godse K, Mehta A, Patil S, Gautam M, Nadkarni N. Omalizumab-a review. Indian J Dermatol. 2015; 60 (4): 381-384.

  48. McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs. 2013; 73 (11): 1197-1212.

  49. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006; 354 (25): 2689-2695.

  50. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017; 72 (4): 519-533.

  51. Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med. 2012; 6: 27-40.

  52. Plosker GL, Keam SJ. Omalizumab. BioDrugs. 2008; 22 (3): 189-204.

  53. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011; 139 (1): 28-35.

  54. Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014; 2 (5): 525-36e1.

  55. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015; 136 (6): 1476-1485.

  56. Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol Pract. 2019; 7 (5): 1379-1392.

  57. Licari A, Manti S, Castagnoli R, Marseglia A, Foiadelli T, Brambilla I et al. Immunomodulation in pediatric asthma. Front Pediatr. 2019; 7: 289.

  58. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651-659.

  59. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016; 38 (9): 2058-70e1.

  60. Poulakos MN, Cargill SM, Waineo MF, Wolford AL Jr. Mepolizumab for the treatment of severe eosinophilic asthma. Am J Health Syst Pharm. 2017; 74 (13): 963-969.

  61. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009; 360 (10): 985-993.

  62. Kips JC, O’Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003; 167 (12): 1655-1659.

  63. Deeks ED, Brusselle G. Reslizumab in eosinophilic asthma: a review. Drugs. 2017; 77 (7): 777-784.

  64. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015; 3 (5): 355-366.

  65. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016; 150 (4): 789-798.

  66. Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015; 33 (1): 14-20.

  67. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017; 9: CD010834.

  68. Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014; 7: 123-130.

  69. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; 378 (26): 2486-2496.

  70. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018; 378 (26): 2475-2485.

  71. Kovalenko P, DiCioccio A, Davis J, Li M, Ardeleanu M, Graham N et al. Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4Rα, in atopic dermatitis patients and normal volunteers. CPT Pharmacometrics Syst Pharmacol. 2016; 5 (11): 617-624.

  72. Matera MG, Calzetta L, Rogliani P, Cazzola M. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respir Med. 2019; 153: 3-13.

  73. Thomson NC, Patel M, Smith AD. Lebrikizumab in the personalized management of asthma. Biologics. 2012; 6: 329-335.

  74. Antoniu SA. Lebrikizumab for the treatment of asthma. Expert Opin Investig Drugs. 2016; 25 (10): 1239-1249.

  75. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016; 4 (10): 781-796.

  76. Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017; 429 (2): 208-219.

  77. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013; 41 (2): 330-338.

  78. Panettieri RA Jr., Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018; 6 (7): 511-525.

  79. Giuffrida P, Caprioli F, Facciotti F, Di Sabatino A. The role of interleukin-13 in chronic inflammatory intestinal disorders. Autoimmun Rev. 2019; 18 (5): 549-555.

  80. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017; 377 (10): 936-946.

  81. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008; 178 (10): 1002-1008.

  82. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010; 181 (2): 116-124.




2020     |     www.medigraphic.com